Endologix to Seek FDA Approval of Nellix EVAS System With Confirmatory Study

 

May 17, 2017—Endologix, Inc. announced it will seek US Food and Drug Administration (FDA) approval for its Nellix endovascular aneurysm sealing (EVAS) system by conducting a confirmatory clinical study using the previously updated instructions for use and Gen2 device design.

The company will collaborate with the FDA on the development of the clinical study protocol, with patient enrollment anticipated to begin in the fourth quarter of 2017. According to the company, premarket approval is estimated to occur in 2020.

Endologix also noted that clinical outcomes with the Nellix EVAS system will be reported at two upcoming medical meetings, Critical Issues in Aortic Endografting in Nuremberg, Germany, on May 19­–20, 2017, and the Vascular Annual Meeting in San Diego, California, on May 31­­–June 3, 2017.

The Nellix EVAS Gen2 system is currently available for commercial use in Europe and other international markets.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.